All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How to treat cytopenic patients with MPN

Feb 27, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

During the MPN Hub steering committee roundtable discussion we were pleased to invite Dr Haifa Kathrin Al-Ali University Hospital Halle (Saale), Halle​, Germany​ to give a presentation on how to treat cytopenic patients with MPN.

How to treat cytopenic patients with MPN

Dr Al-Ali opens the presentation by outlining the differences between cytopenic and myeloproliferative MF before giving an overview of the various treatment options available to cytopenic patients and their role in the clinical landscape. She concludes by highlighting investigational agents currently in clinical trials.